Last reviewed · How we verify
Active Pharmaceutical Ingredient
At a glance
| Generic name | Active Pharmaceutical Ingredient |
|---|---|
| Also known as | (API), API |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Glomerular filtration rate decreased
- Lymphocyte count decreased
- Haemoglobin decreased
- Anaemia
- Hyperglycaemia
- Application site pruritus
- Blood glucose increased
- Application site pain
- Application site dryness
- Blood creatinine increased
- Aspartate aminotransferase increased
- Pyrexia
Key clinical trials
- Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) (PHASE2)
- Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia (PHASE2)
- Sodium Aescinate for the Treatment of Low Back Pain (LBP) in Adults (PHASE1)
- Effectiveness of Topical Menthol as A Cooling Method During Exercise in A Recreational Runner Population (PHASE2, PHASE3)
- Efavirenz for the Treatment of Creutzfeldt-Jakob Disease (PHASE3)
- Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) (PHASE2, PHASE3)
- A Study of Auxora in Patients With Critical COVID-19 Pneumonia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Active Pharmaceutical Ingredient CI brief — competitive landscape report
- Active Pharmaceutical Ingredient updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI